Next-generation vaccines for substance use disorders

作     者：Kaixuan Wang Hongshuang Wang Xiaohui Wang 

作者机构：Laboratory of Chemical BiologyChangchun Institute of Applied ChemistryChinese Academy of SciencesChangchunJilin 130022China School of Applied Chemistry and EngineeringUniversity of Science and Technology of ChinaHefeiAnhui 230026China 

出 版 物：《Zoological Research》 (动物学研究（英文）)

年 卷 期：2024年第45卷第3期

页      面：707-708页

核心收录：

学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学] 

基　　金：supported by the National Science Foundation of China(T2350008,T2341003,22207103) STI2030-Major Projects(2021ZD0203000(2021ZD0203003))。 

主　　题：disorders treatment consequences 

摘      要：Substance use disorders(SUDs)impact an estimated 300 million people worldwide,significantly impairing both health and social functioning.These disorders are marked by an inability to regulate substance use,despite the harmful consequences.Addiction affects various neurotransmitter systems,including dopamine,serotonin,γ-aminobutyric acid(GABA),and glutamate,each of which plays a role in the reward,stress,and self-control pathways of the brain(Koob&Volkow,2016).While significant advances have been made in neuroscience,our understanding of how these neurotransmitter systems interact and contribute to addiction is still evolving.This knowledge gap represents a significant challenge in the formulation of effective treatments for SUDs.At present,the US Food and Drug Administration(FDA)has approved pharmacological treatments for alcohol,nicotine,and opioid use disorders(Vasiliu,2022);however,no such treatments have been authorized for SUDs in general,or specifically for stimulant use disorders,such as cocaine and methamphetamine addiction.Notably,the FDA has not approved any new drugs for SUD treatment in the past 40 years.